Ioannis griveas (51 Ergebnisse)

Paperback. Zustand: Brand New. 68 pages. 8.66x5.91x0.16 inches. In Stock.

Zustand: New. pp. 72.

Zustand: New. pp. 72.

Zustand: New. pp. 72.

paperback. Zustand: New. NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Taschenbuch. Zustand: Neu. Eficacia y seguridad de la etelcalcetida | En los pacientes que reciben hemodiálisis con hiperparatiroidismo:Datos de la vida real | Ioannis Griveas | Taschenbuch | 64 S. | Spanisch | 2020 | Editorial Académica Española | EAN 9786200386489 | Verantwortliche Person für die EU: BoD - Books on Demand, In de Tarpen 42, 22848 Norderstedt, info[at]bod[dot]de | Anbieter: preigu.…

Zustand: New.

Zustand: New. Brand New ! Fast Delivery This is an International Edition and ship within 24-48 hours. Deliver by FedEx and Dhl, & Aramex, UPS, & USPS and we do accept APO and PO BOX Addresses. Order can be delivered worldwide within 6-10 days and we do have flat rate for up to 2LB. Extra shipping charges will be requested if the Book weight is more than 5 LB. This Item May be shipped from India, United states & United Kingdom. Depending on your location and availability.…

Zustand: Used: Like New. LIVRE A L?ETAT DE NEUF. EXPEDIE SOUS 3 JOURS OUVRES. NUMERO DE SUIVI COMMUNIQUE AVANT ENVOI, EMBALLAGE RENFORCE. EAN:9781634832229.

Taschenbuch. Zustand: Neu. Efficacité et sécurité de l'etelcalcetide | Chez les patients sous hémodialyseavec hyperparathyroïdie:Données réelles | Ioannis Griveas | Taschenbuch | 64 S. | Französisch | 2020 | Éditions universitaires européennes | EAN 9786139560561 | Verantwortliche Person für die EU: BoD - Books on Demand, In de Tarpen 42, 22848 Norderstedt, info[at]bod[dot]de | Anbieter: preigu. …

Taschenbuch. Zustand: Neu. Doeltreffendheid en de veiligheid van etelcalcetide | Bij patiënten die hemodialyse krijgen met hyperparathyroïdie:Gegevens uit het echte leven | Ioannis Griveas | Taschenbuch | 64 S. | Niederländisch | 2020 | GlobeEdit | EAN 9786200597434 | Verantwortliche Person für die EU: GlobeEdit, Brivibas Gatve 197, 1039 RIGA, LETTLAND, customerservice[at]vdm-vsg[dot]de | Anbieter: preigu.…

Taschenbuch. Zustand: Neu. Eficácia e segurança de etelcalcetide | Em pacientes que recebem hemodiálise com hiperparatiroidismo:Dados da vida real | Ioannis Griveas | Taschenbuch | Portugiesisch | 2020 | Novas Edições Acadêmicas | EAN 9786200790446 | Verantwortliche Person für die EU: Novas Edicoes Academicas, Brivibas Gatve 197, 1039 RIGA, LETTLAND, customerservice[at]vdm-vsg[dot]de | Anbieter: preigu.…

Taschenbuch. Zustand: Neu. Efficacia e sicurezza di etelcalcetide | Nei pazienti sottoposti a emodialisicon iperparatiroidismo:Dati della vita reale | Ioannis Griveas | Taschenbuch | 64 S. | Italienisch | 2020 | Edizioni Accademiche Italiane | EAN 9786200830180 | Verantwortliche Person für die EU: Edizioni Accademiche Italiane, Brivibas Gatve 197, 1039 RIGA, LETTLAND, customerservice[at]vdm-vsg[dot]de | Anbieter: preigu. …

Taschenbuch. Zustand: Neu. Wirksamkeit und Sicherheit von Elektrocalcetid | Bei Patienten, die eine Hämodialyse erhalten mit Hyperparathyreoidismus:Daten aus dem wirklichen Leben | Ioannis Griveas | Taschenbuch | 64 S. | Deutsch | 2020 | AV Akademikerverlag | EAN 9786200662217 | Verantwortliche Person für die EU: AV Akademikerverlag, Brivibas Gatve 197, 1039 RIGA, LETTLAND, customerservice[at]vdm-vsg[dot]de | Anbieter: preigu.…

Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Secondary hyperparathyroidism (sHPT) is common in hemodialysis (HD) patients. The present study aimed to evaluate the efficacy and safety profile of etelcalcetide, a new peptide calcium-sensing receptor (CaSR) agonist in an observational study for the treatment of sHPT in CKD patients on HD.60 HD stable patients with sHPT were received etelcalcetide for 10 months. PTH levels, Ca, Ph, alb were measured before starting etelcalcetide and every month until the end of the protocol. Heart function was also evaluated. The primary outcome was estimation of PTH concentrations at the end of the treatment period. Secondary outcomes were monitoring of corrected serum Ca, ph. Adverse events were also evaluated. PTH significantly decreased from the first month of the treatment with etelcalcetide until the end of the study period. We also noticed significant reduction of the ph levels even from the second month of treatment. This trend also carried out for 8 months. Heart function remained stable. Ca levels remained in accepted area. None of the patients dropped out due to adverse events.Etelcalcetide is safe, well tolerated and effective in reducing PTH in HD patients with sHPT. 68 pp. Englisch.…

Taschenbuch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Secondary hyperparathyroidism (sHPT) is common in hemodialysis (HD) patients. The present study aimed to evaluate the efficacy and safety profile of etelcalcetide, a new peptide calcium-sensing receptor (CaSR) agonist in an observational study for the treatment of sHPT in CKD patients on HD.60 HD stable patients with sHPT were received etelcalcetide for 10 months. PTH levels, Ca, Ph, alb were measured before starting etelcalcetide and every month until the end of the protocol. Heart function was also evaluated. The primary outcome was estimation of PTH concentrations at the end of the treatment period. Secondary outcomes were monitoring of corrected serum Ca, ph. Adverse events were also evaluated. PTH significantly decreased from the first month of the treatment with etelcalcetide until the end of the study period. We also noticed significant reduction of the ph levels even from the second month of treatment. This trend also carried out for 8 months. Heart function remained stable. Ca levels remained in accepted area. None of the patients dropped out due to adverse events.Etelcalcetide is safe, well tolerated and effective in reducing PTH in HD patients with sHPT. …

Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware 68 pp. Englisch.

Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Griveas IoannisIoannis Griveas, MD, PhD, is Consultant Nephrologist, Medical Director of the Nephrology Department of Army Share Fund Hospital of Athens, Greece and Professor-Advisor at Hellenic Open University. Previous books:Pri.…

Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Secondary hyperparathyroidism (sHPT) is common in hemodialysis (HD) patients. The present study aimed to evaluate the efficacy and safety profile of etelcalcetide, a new peptide calcium-sensing receptor (CaSR) agonist in an observational study for the treatment of sHPT in CKD patients on HD.60 HD stable patients with sHPT were received etelcalcetide for 10 months. PTH levels, Ca, Ph, alb were measured before starting etelcalcetide and every month until the end of the protocol. Heart function was also evaluated. The primary outcome was estimation of PTH concentrations at the end of the treatment period. Secondary outcomes were monitoring of corrected serum Ca, ph. Adverse events were also evaluated.PTH significantly decreased from the first month of the treatment with etelcalcetide until the end of the study period.We also noticed significant reduction of the ph levels even from the second month of treatment. This trend also carried out for 8 months. Heart function remained stable. Ca levels remained in accepted area. None of the patients dropped out due to adverse events.Etelcalcetide is safe, well tolerated and effective in reducing PTH in HD patients with sHPT. 64 pp. Spanisch.…

Taschenbuch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Secondary hyperparathyroidism (sHPT) is common in hemodialysis (HD) patients. The present study aimed to evaluate the efficacy and safety profile of etelcalcetide, a new peptide calcium-sensing receptor (CaSR) agonist in an observational study for the treatment of sHPT in CKD patients on HD.60 HD stable patients with sHPT were received etelcalcetide for 10 months. PTH levels, Ca, Ph, alb were measured before starting etelcalcetide and every month until the end of the protocol. Heart function was also evaluated. The primary outcome was estimation of PTH concentrations at the end of the treatment period. Secondary outcomes were monitoring of corrected serum Ca, ph. Adverse events were also evaluated. PTH significantly decreased from the first month of the treatment with etelcalcetide until the end of the study period. We also noticed significant reduction of the ph levels even from the second month of treatment. This trend also carried out for 8 months. Heart function remained stable. Ca levels remained in accepted area. None of the patients dropped out due to adverse events.Etelcalcetide is safe, well tolerated and effective in reducing PTH in HD patients with sHPT. …

Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Secondary hyperparathyroidism (sHPT) is common in hemodialysis (HD) patients. The present study aimed to evaluate the efficacy and safety profile of etelcalcetide, a new peptide calcium-sensing receptor (CaSR) agonist in an observational study for the treatment of sHPT in CKD patients on HD.60 HD stable patients with sHPT were received etelcalcetide for 10 months. PTH levels, Ca, Ph, alb were measured before starting etelcalcetide and every month until the end of the protocol. Heart function was also evaluated. The primary outcome was estimation of PTH concentrations at the end of the treatment period. Secondary outcomes were monitoring of corrected serum Ca, ph. Adverse events were also evaluated. PTH significantly decreased from the first month of the treatment with etelcalcetide until the end of the study period. We also noticed significant reduction of the ph levels even from the second month of treatment. This trend also carried out for 8 months. Heart function remained stable. Ca levels remained in accepted area. None of the patients dropped out due to adverse events.Etelcalcetide is safe, well tolerated and effective in reducing PTH in HD patients with sHPT.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 68 pp. Englisch.…

Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -L'hyperparathyroïdie secondaire est fréquente chez les patients hémodialysés (HD). La présente étude vise à évaluer l'efficacité et le profil de sécurité de l'etelcalcetide, un nouvel agoniste peptidique du récepteur de détection du calcium (CaSR), dans le cadre d'une étude d'observation pour le traitement de la sHPT chez les patients atteints d'IRC en hémodialyse.60 patients atteints d'HM stable et atteints d'HPTs ont reçu de l'etelcalcetide pendant 10 mois. Les niveaux de PTH, Ca, Ph, aube ont été mesurés avant le début de l'administration de l'etelcalcetide et tous les mois jusqu'à la fin du protocole. La fonction cardiaque a également été évaluée. Le principal résultat a été l'estimation des concentrations de PTH à la fin de la période de traitement. Les résultats secondaires étaient la surveillance des taux sériques corrigés de Ca, Ph. Les effets indésirables ont également été évalués.La PTH a diminué de manière significative à partir du premier mois de traitement par l'etelcalcetide jusqu'à la fin de la période d'étude.Nous avons également constaté une réduction significative des niveaux de ph même à partir du deuxième mois de traitement. 64 pp. Französisch.…

Taschenbuch. Zustand: Neu. Efficacy and safetyof etelcalcetide | In patients receiving hemodialysis with hyperparathyroidism:Real life data | Ioannis Griveas | Taschenbuch | Englisch | 2019 | LAP LAMBERT Academic Publishing | EAN 9786200457646 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu Print on Demand. …

Taschenbuch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Secondary hyperparathyroidism (sHPT) is common in hemodialysis (HD) patients. The present study aimed to evaluate the efficacy and safety profile of etelcalcetide, a new peptide calcium-sensing receptor (CaSR) agonist in an observational study for the treatment of sHPT in CKD patients on HD.60 HD stable patients with sHPT were received etelcalcetide for 10 months. PTH levels, Ca, Ph, alb were measured before starting etelcalcetide and every month until the end of the protocol. Heart function was also evaluated. The primary outcome was estimation of PTH concentrations at the end of the treatment period. Secondary outcomes were monitoring of corrected serum Ca, ph. Adverse events were also evaluated.PTH significantly decreased from the first month of the treatment with etelcalcetide until the end of the study period.We also noticed significant reduction of the ph levels even from the second month of treatment. This trend also carried out for 8 months. Heart function remained stable. Ca levels remained in accepted area. None of the patients dropped out due to adverse events.Etelcalcetide is safe, well tolerated and effective in reducing PTH in HD patients with sHPT. …

Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. &Uumlber den AutorrnrnIoannis Griveas, MD, PhD, is Consultant Nefrologist, Medisch Directeur van de afdeling Nefrologie van het Army Share Fund Hospital van Athene, Griekenland en Professor-Advisor aan de Hellenic Open Universiteit.Vorige boeke.…

Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Secundaire hyperparathyroïdie (sHPT) komt veel voor bij hemodialyse (HD) patiënten. Deze studie had tot doel de werkzaamheid en het veiligheidsprofiel van etelcalcetide, een nieuwe peptide calcium-sensing receptor (CaSR) agonist, te evalueren in een observatiestudie voor de behandeling van sHPT bij CKD-patiënten op HD.60 HD stabiele patiënten met sHPT werden gedurende 10 maanden etelcalcetide toegediend. PTH-niveaus, Ca, Ph, alb werden gemeten voor het starten van etelcalcetide en elke maand tot het einde van het protocol. De hartfunctie werd ook geëvalueerd. De primaire uitkomst was een schatting van de PTH-concentraties aan het einde van de behandelingsperiode. Secundaire resultaten waren monitoring van gecorrigeerd serum Ca, ph. Bijwerkingen werden ook geëvalueerd.PTH daalde significant vanaf de eerste maand van de behandeling met etelcalcetide tot het einde van de studieperiode.We merkten ook een significante vermindering van de ph-niveaus, zelfs vanaf de tweede maand van de behandeling. Deze trend werd ook gedurende 8 maanden uitgevoerd. De hartfunctie bleef stabiel. Ca niveaus bleven in het geaccepteerde gebied. Geen van de patiënten viel af als gevolg van bijwerkingen. 64 pp. Niederländisch.…

Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Secondary hyperparathyroidism (sHPT) is common in hemodialysis (HD) patients. The present study aimed to evaluate the efficacy and safety profile of etelcalcetide, a new peptide calcium-sensing receptor (CaSR) agonist in an observational study for the treatment of sHPT in CKD patients on HD.60 HD stable patients with sHPT were received etelcalcetide for 10 months. PTH levels, Ca, Ph, alb were measured before starting etelcalcetide and every month until the end of the protocol. Heart function was also evaluated. The primary outcome was estimation of PTH concentrations at the end of the treatment period. Secondary outcomes were monitoring of corrected serum Ca, ph. Adverse events were also evaluated. PTH significantly decreased from the first month of the treatment with etelcalcetide until the end of the study period. We also noticed significant reduction of the ph levels even from the second month of treatment. This trend also carried out for 8 months. Heart function remained stable. Ca levels remained in accepted area. None of the patients dropped out due to adverse events.Etelcalcetide is safe, well tolerated and effective in reducing PTH in HD patients with sHPT.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 68 pp. Englisch.…

Taschenbuch. Zustand: Neu. Efficacy and safety of etelcalcetide | In patients receiving hemodialysis with hyperparathyroidism:Real life data Second Edition | Ioannis Griveas | Taschenbuch | Englisch | 2026 | LAP LAMBERT Academic Publishing | EAN 9786209613890 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu Print on Demand. …

Taschenbuch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - L'hyperparathyroïdie secondaire est fréquente chez les patients hémodialysés (HD). La présente étude vise à évaluer l'efficacité et le profil de sécurité de l'etelcalcetide, un nouvel agoniste peptidique du récepteur de détection du calcium (CaSR), dans le cadre d'une étude d'observation pour le traitement de la sHPT chez les patients atteints d'IRC en hémodialyse.60 patients atteints d'HM stable et atteints d'HPTs ont reçu de l'etelcalcetide pendant 10 mois. Les niveaux de PTH, Ca, Ph, aube ont été mesurés avant le début de l'administration de l'etelcalcetide et tous les mois jusqu'à la fin du protocole. La fonction cardiaque a également été évaluée. Le principal résultat a été l'estimation des concentrations de PTH à la fin de la période de traitement. Les résultats secondaires étaient la surveillance des taux sériques corrigés de Ca, Ph. Les effets indésirables ont également été évalués.La PTH a diminué de manière significative à partir du premier mois de traitement par l'etelcalcetide jusqu'à la fin de la période d'étude.Nous avons également constaté une réduction significative des niveaux de ph même à partir du deuxième mois de traitement.…

Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Secondary hyperparathyroidism (sHPT) is common in hemodialysis (HD) patients. The present study aimed to evaluate the efficacy and safety profile of etelcalcetide, a new peptide calcium-sensing receptor (CaSR) agonist in an observational study for the treatment of sHPT in CKD patients on HD.60 HD stable patients with sHPT were received etelcalcetide for 10 months. PTH levels, Ca, Ph, alb were measured before starting etelcalcetide and every month until the end of the protocol. Heart function was also evaluated. The primary outcome was estimation of PTH concentrations at the end of the treatment period. Secondary outcomes were monitoring of corrected serum Ca, ph. Adverse events were also evaluated.PTH significantly decreased from the first month of the treatment with etelcalcetide until the end of the study period.We also noticed significant reduction of the ph levels even from the second month of treatment. This trend also carried out for 8 months. Heart function remained stable. Ca levels remained in accepted area. None of the patients dropped out due to adverse events.Etelcalcetide is safe, well tolerated and effective in reducing PTH in HD patients with sHPT.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 64 pp. Spanisch.…